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OBJECTIVES: To evaluate cost-effectiveness of entecavir (ETV)
vs. lamivudine (LVD) in treating CHB in Poland. METHODS:
A decision tree model was developed to project over a period of
10 years the number of cirrhosis (compensated and decompen-
sated) and hepatocellular carcinoma events based on serum HB
viral-DNA levels. Two hypothetical cohorts of CHB patients
treated for 2 years were studied: 1) nucleoside-naïve patients
treated with ETV (0.5 mg/day) vs. LVD (100 mg/day) and ade-
fovir (ADV) as salvage therapy in case of LVD resistance; and 2)
LVD-refractory patients treated with ETV (1 mg/day) vs. ADV
(10 mg/day). Effectiveness was measured as quality-adjusted life
year (QALY). Efﬁcacy data, the risk predicting models, utility
scores and medical costs for CHB disease stages were obtained
from published literatures. Life expectancy was estimated using
Polish life tables and published literature. A Polish health care
payer perspective was considered and a 5% discount rate was
used for both costs and outcomes. Sensitivity analyses to treat-
ment patterns, costs and utilities were performed. RESULTS:
Resistance to treatment with LVD was associated with lower efﬁ-
cacy and increased costs. In nucleoside-naïve HBeAg+ patients,
ETV compared with LVD therapy with ADV salvage saved
369,676/373,701 PLN and gained 28/30 QALYs for 100
men/women, respectively. For nucleoside-naïve HBeAg-patients,
savings were 185,066/187,564 PLN and QALYs gained 13/15
for 100 men/women, respectively. In LVD-refractory patients,
ETV therapy was associated with savings of 424,383/429,007
PLN and QALYs gained of 26/29 for 100 men/women, respec-
tively. Results were robust to sensitivity analyses. CONCLU-
SION: This cost-effectiveness analysis suggests that in the Polish
health care system, ETV dominates LVD to treat CHB in nucle-
oside-naïve and LVD-refractory patients. Due to differences in
life expectancy between men and women, cost-effectiveness
results are more favorable for women with CHB.
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OBJECTIVES: Linezolid, an oxazolidinone antibiotic, has been
shown to be effective in the treatment of complicated skin and
soft-tissue infections (cSSTI) and nosocomial pneumonia (NP)
including ventilator-associated pneumonia (VAP) caused by
methicillin-resistant Staphylococcus aureus (MRSA) in hospital-
ized patients. However, hospital use of linezolid has been limited
by high acquisition cost compared with other antibiotics. The
objective was to compare the consistency of cost-effectiveness
ﬁndings of linezolid across different health care systems.
METHODS: Separate studies were conducted in Brazil, Italy,
Germany, Spain, and the US to estimate the cost-effectiveness of
linezolid for the treatment of gram-positive infections. In all
studies (except US), a decision-analytic model was used to
predict the cost-effectiveness of linezolid vs vancomycin or
teicoplanin in each country. For the US, resource use data were
obtained from a multicenter trial. For all other countries, clini-
cal efﬁcacy data were obtained from multinational clinical trials,
cost data were based on published literature and local govern-
ment sources, and a Delphi panel comprising local experts pro-
vided input into health care resource utilization data. RESULTS:
In all health care systems, linezolid was cost-effective due to its
superior clinical cure and survival (in NP). In cSSTI, total treat-
ment costs were less expensive by $153 (Germany), $787 (Spain)
and $873 (US) mainly due to reduction in length of stay. In Italy,
treatment costs were similar (linezolid was $77 more). In VAP,
cost per life year saved was $380 in Spain and cost saving in
Brazil. Similarly, cost for life year gained for NP was $460.
CONCLUSION: All studies showed that despite higher acquisi-
tion cost, linezolid is either cost-saving or cost-effective for hos-
pitalized patients with gram-positive infections across multiple
health care systems due to its higher clinical efﬁcacy in terms of
cure and survival rates.
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OBJECTIVES: Darunavir (TMC114; DRV) is a novel protease
inhibitor (PI) with demonstrated superior efﬁcacy to currently
available PIs for the treatment of HIV infection in treatment-
experienced adults who have failed prior antiretroviral therapy.
We evaluated the cost-effectiveness (CE), from a Canadian
provincial Ministry of Health perspective, of ritonavir-boosted
DRV (DRV/r) plus an optimized background regimen (OBR)
compared to currently available PIs plus OBR (control).
METHODS: A Markov model with 3-month cycles was devel-
oped to follow patients through 6 possible health states deﬁned
by CD4 cell count ranges. Costs (in 2006 Canadian dollars) were
assumed to accrue based on estimates of health care services used
during each health state. Each health state also had an associ-
ated utility value. Cost, utility, and mortality data were estimated
from published Canadian sources. Transition probabilities were
calculated from clinical trials. Both costs and outcomes were dis-
counted at 5%/year. Two analyses were conducted: 1) incre-
mental cost/additional person with viral load <50 copies/mL at
48 weeks; 2) incremental lifetime cost/quality-adjusted life-year
(QALY) gained. Extensive sensitivity and variability (assessing
impact of practice patterns, population and model characteris-
tics) analyses were performed. RESULTS: DRV/r is associated
with a 36% absolute increase in probability of achieving viral
load <50 copies/mL at 48 weeks and a gain of 1.27 QALYs over
a lifetime. The incremental cost/additional person with viral load
<50 copies/mL was $9897; the incremental cost/QALY gained
was $30,907. Sensitivity and variability analyses showed results
were robust. For most of the credible uncertainty ranges, the CE
ratio remained less than $50,000/QALY gained. Variability
analyses showed CE ratios ranged $23,283–$34,667 depending
most heavily on the assumed amount of tipranavir use in the
model control arm and enfuvirtide use in the OBR. CONCLU-
SION: When compared to current standard of care, DRV/r plus
OBR is cost-effective in treatment-experienced adults who have
failed prior antiretroviral therapy.
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BACKGROUND: The cost-effectiveness of routine inﬂuenza vac-
cination in people over 65 is accepted. This study compares the
incremental cost-effectiveness of the MF59 adjuvanted vaccine
Fluad®* to non-adjuvanted vaccines in France in situations where
the circulating strain matches the strain prepared in the vaccine,
and also where there is antigenic drift—where the circulating
strain differs slightly from the one included in the vaccine.
METHODS: A decision analysis model was developed using evi-
